Form 8-K - Current report:
SEC Accession No. 0001193805-25-000454
Filing Date
2025-04-09
Accepted
2025-04-09 17:26:07
Documents
19
Period of Report
2025-04-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 e664373_8k-immunic.htm   iXBRL 8-K 30387
2 e664373_ex4-1.htm EX-4.1 98893
3 e664373_ex5-1.htm EX-5.1 9504
4 e664373_ex10-1.htm EX-10.1 51187
5 e664373_ex10-2.htm EX-10.2 182724
6 e664373_ex99-1.htm EX-99.1 12779
10 GRAPHIC image_001.jpg GRAPHIC 6113
  Complete submission text file 0001193805-25-000454.txt   665830

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE imux-20250409.xsd EX-101.SCH 3002
8 XBRL LABEL FILE imux-20250409_lab.xml EX-101.LAB 34239
9 XBRL PRESENTATION FILE imux-20250409_pre.xml EX-101.PRE 22350
21 EXTRACTED XBRL INSTANCE DOCUMENT e664373_8k-immunic_htm.xml XML 3785
Mailing Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036
Business Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036 (332) 255-9818
IMMUNIC, INC. (Filer) CIK: 0001280776 (see all company filings)

EIN.: 562358443 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36201 | Film No.: 25825989
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)